A total scale of 30 billion! The first national-level mother fund in the foreign trade and economic field is being raised, introducing listed company LP Jinbo Bio and Joinn Laboratories.

① The Innovation and Development Guidance Fund for Service Trade is a national-level fund initiated by the Ministry of Finance, the Ministry of Commerce, and China Merchants Group, approved by the State Council, with a total scale of 30 billion yuan. ② An IR practitioner stated to the Star Daily that the second phase of the service trade fund inviting listed companies to become LPs may be a more market-oriented signal.

cls.cnDec 13, 2024 05:33 ET

Q3 revenue growth rate dropped to 1%. Can the next approved botox product in China be featured on imeik technology development? | Interpretations

①In the first three quarters, imeik technology development's performance has shown some growth, but the revenue and net income attributable to shareholders have slowed down. ②In order to seek new growth points, imeik technology development's research and development expenses continue to rise, focusing on the layout of weight management drugs, botulinum toxin and other fields.

cls.cnOct 23, 2024 11:43 ET

imeik technology development Q3 revenue increased by 1.10% year-on-year, net income increased by 2.13% | Financial Report Watch

In the first three quarters, the company achieved revenue of approximately 2.376 billion yuan, a year-on-year increase of 9.46%; net income was approximately 1.586 billion yuan, a year-on-year increase of 11.79%. The operational scale of the company is steadily increasing, and the profitability meets market expectations.

wallstreetcnOct 23, 2024 09:43 ET

Revenue and net profit growth rates have both slowed down. Is Jinbo Life Sciences, which has been frequently accused, feeling the pressure? | interpretations

①In the first three quarters of this year, Jinbo Bioscience's performance still maintained a high-speed growth, but the growth rate slowed down compared to the same period last year. ②In addition, the rapid growth of the company's sales expenses was caused by reasons such as the expansion of the sales team. ③The company's core product, Weiyi Mei, is facing multiple pressures, so Jinbo Bioscience has frequently stated its posture in the face of internet-related sales platforms.

cls.cnOct 21, 2024 12:03 ET

The performance has "double declined" and the stock price "continues to fall". Why did bloomage biotechnology corporation limited's growth engine stall?

① Bloomage Biotechnology Corporation Limited once again experienced a double decline in revenue and net income in the first half of the year. The company achieved revenue of 2.81 billion yuan, a year-on-year decrease of 8.61%; achieved net income of 0.342 billion yuan, a year-on-year decrease of 19.51%; ② Although the raw materials business and medical terminal business performed well, the two major new sectors that have been heavily promoted in recent years - functional skincare products and functional food - have experienced a simultaneous decline in growth rates.

cls.cnAug 23, 2024 22:23 ET

The gross margin of injection products in the solution category has declined, and the imeik technology development's Q2 performance growth rate has dropped to single digits| Speed reading announcement.

①Imeik Technology Development's H1 revenue and net income growth rate slowed down. ②The gross margin of solution injection products has declined, and its proportion in total revenue has further decreased. ③In addition to laying out research and development pipelines for botulinum toxin, GLP-1 drugs, the company is also further expanding in the medical beauty equipment field.

cls.cnAug 21, 2024 10:16 ET